ABSTRACT
Background Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. The ability to correctly predict the diagnosis of Alzheimer’s disease in its earliest stages can help physicians make more informed clinical decisions on therapy plans.
Objective To determine whether the unsupervised discovering of latent classes of subjects with mild cognitive impairment (MCI) may be useful in finding different prodromal AD stages and/or subjects that have a low MCI to AD conversion risk.
Methods 18 features relevant with the MCI to AD conversion process described 681 subjects with early MCI. Subjects were split into training (70%) and validation (30%) sets. Subjects from the training set were analyzed using consensus clustering and Gaussian mixture models (GMM) were used to describe the shape of the discovered latent classes. The discovered GMM predicted the latent class of the validation set. Finally, descriptive statistics, rates of conversion, and odds ratios (OR) were computed for each discovered class.
Results Through consensus clustering we discovered three different clusters among MCI subjects. The three clusters were associated with low-risk (OR = 0.12, 95%CI = 0.04 to 0.3|), medium-risk (OR = 1.33, 95%CI = 0.75 to 2.37), and high-risk (OR = 3.02, 95%CI = 1.64 to 5.57) of converting from MCI to AD, with the high-risk and low-risk groups highly contrasting. Hence, prodromal AD subjects were present on only two clusters.
Conclusion We successfully discovered three different latent classes among MCI subjects with varied risk of MCI-to-AD conversion through consensus clustering. Two of the discovered classes may represent two different prodromal presentations of the Alzheimer’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CONACYT (Mexico gavernment) supports this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
0000-0001-5200-1193
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in the preparation of this study was obtained from the TADPOLE challenge standard data sets. The TADPOLE sets were derived from the Alzheimers Disease Neuroimaging Initiative (ADNI) study (adni.loni.usc.edu).
